Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing

BACKGROUND: Cemiplimab, a high-affinity, potent human immunoglobulin G4 monoclonal antibody to programmed cell death-1 demonstrated antitumor activity in a Phase 1 advanced cutaneous squamous cell carcinoma (CSCC) expansion cohort (NCT02383212) and the pivotal Phase 2 study (NCT02760498). Here we re...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:J Immunother Cancer
Hoofdauteurs: Rischin, Danny, Migden, Michael R, Lim, Annette M, Schmults, Chrysalyne D, Khushalani, Nikhil I, Hughes, Brett G M, Schadendorf, Dirk, Dunn, Lara A, Hernandez-Aya, Leonel, Chang, Anne Lynn S, Modi, Badri, Hauschild, Axel, Ulrich, Claas, Eigentler, Thomas, Stein, Brian, Pavlick, Anna C, Geiger, Jessica L, Gutzmer, Ralf, Alam, Murad, Okoye, Emmanuel, Mathias, Melissa, Jankovic, Vladimir, Stankevich, Elizabeth, Booth, Jocelyn, Li, Siyu, Lowy, Israel, Fury, Matthew G, Guminski, Alexander
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: BMJ Publishing Group 2020
Onderwerpen:
Clinical/Translational Cancer Immunotherapy
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7304829/
https://ncbi.nlm.nih.gov/pubmed/32554615
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-000775
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items